- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
BioPorto is seeking regulatory pathways and activating its first clinical site in collaboration with Massachusetts General Hospital.
1 report, 1 independent
Updated Aug 18
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BioPorto is seeking regulatory pathways and activating its first clinical site in collaboration with Massachusetts General Hospital.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- Oversight failures and regulatory inertia in the U.S. drug approval process were exposed on August 3rd, involving the FDA and Merck.
The entities involved
Related events
- A study author is based in Johns Hopkins School of Medicine, and the research is connected to Baltimore, now involving the FDA for drug approval.
- Future sales of a product are contingent upon obtaining the necessary FDA registration and labeling, while the state simultaneously announces actions to remove regulatory barriers.
- Fate Therapeutics, based in San Diego, is seeking support for an accelerated regulatory pathway from the FDA.
- FDA approval enables commercial opportunity involving CBRE Group.
- FDA clearance enables market entry into the U.S. for an unnamed company, which is also navigating the long-term regulatory process in Japan.